FDA Fast-Tracks Hope for Pancreatic Cancer | Gainesville News

FDA fast-tracks Rasonque, a groundbreaking drug for stage four pancreatic cancer, offering patients nearly doubled survival rates—13.2 months vs. 6.7—with just one daily dose, bringing renewed hope to those with limited treatment options. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/51c225934d8847af